Simple Plex Human VEGF-C Cartridge
ProteinSimple, part of Bio-Techne | Catalog # SPCKB-PS-000224
Key Product Details
Assay Length
Sample Type & Volume Required Per Well*
Sensitivity
Assay Range
Simple Plex Human VEGF-C Cartridge Summary
*The Sample Volume represented is based on the amount of sample incorporated into the reaction after taking into account the assay's minimum required dilution for a given matrix. Serial dilution may be necessary to achieve some of the final sample volumes represented.
Compatible Instruments
Ella Automated Immunoassay System
Product Specifications
Assay Type
Format
Reactivity
Specificity
Cross-reactivity
Interference
Precision
Intra-Assay Precision (Precision within an assay) Each control was tested multiple times in one VEGF-C assay.
Inter-Assay Precision (Precision between assays) Replicates of each VEGF-C control were tested in multiple assays performed by at least three technicians using two lots of reagents for human VEGF-C.
Platelet-poor EDTA Plasma, Platelet-poor Heparin Plasma, Serum
| Intra-Assay Precision | Inter-Assay Precision | |||
|---|---|---|---|---|
| Sample | 1 | 2 | 1 | 2 |
| n | 16 | 16 | 19 | 19 |
| Mean (pg/mL) | 149 | 7683 | 151 | 7918 |
| Standard Deviation | 13.7 | 531 | 13.4 | 727 |
| CV% | 9.2 | 6.9 | 8.8 | 9.2 |
Recovery for Simple Plex Human VEGF-C Cartridge
Recovery for the human VEGF-C assays was evaluated at three different spiked concentrations of VEGF-C protein.
| Sample Type | Average % Recovery | Range % |
|---|---|---|
| Platelet-poor EDTA Plasma (n=4) | 111 | 92-122 |
| Platelet-poor Heparin Plasma (n=4) | 111 | 90-123 |
Linearity
Samples containing and/or spiked with high concentrations of human VEGF-C were serially diluted with Sample Diluent to produce samples within the dynamic range of the assay
Scientific Data Images for Simple Plex Human VEGF-C Cartridge
Human VEGF-C Ella Assay Standard Curve
Preparation and Storage
Shipping
Stability & Storage
Background: VEGF-C
Vascular endothelial growth factor C (VEGF-C) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-C containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. Both the ligand and receptor are usually co-expressed at sites of lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, neoangiogenesis, and vessel sprouting, resulting in enhanced lymph flow and metastasis to regional lymph nodes.
Long Name
Alternate Names
Gene Symbol
Additional VEGF-C Products
Product Documents for Simple Plex Human VEGF-C Cartridge
Product Specific Notices for Simple Plex Human VEGF-C Cartridge
For research use only